Why epilepsy trial monitoring matters
Epilepsy affects approximately 50 million people worldwide, making it one of the most common serious neurological conditions globally. Despite more than 30 approved antiseizure medications (ASMs), roughly 30% of patients remain drug-resistant — defined as failure of two or more adequately dosed ASMs — and continue to experience seizures that substantially impair quality of life and carry mortality risk (SUDEP). This large, persistent treatment gap makes epilepsy one of the most active areas in CNS drug development, with a pipeline spanning novel small molecules, biologics, gene therapy, and neuromodulation devices.
For pharma and biotech strategy teams, epilepsy has a unique competitive structure. The broader epilepsy population represents a high-volume market for new ASMs with improved tolerability, while rare genetic epilepsies (Dravet syndrome, Lennox-Gastaut syndrome, CDKL5 deficiency disorder, KCNQ2-related epilepsy) represent smaller but commercially high-value orphan opportunities with expedited regulatory pathways, limited existing competition, and strong advocacy networks that accelerate trial enrollment. Both segments require distinct monitoring strategies — and a daily digest that spans the full epilepsy landscape is essential for any team active in this space.
Key signals that professionals track:
- New ASM trials in drug-resistant focal epilepsy — the largest addressable unmet-need population, where several novel sodium channel modulators and AMPA receptor antagonists are in Phase 2/3 development
- Rare genetic epilepsy trials for Dravet syndrome (SCN1A loss-of-function), Lennox-Gastaut syndrome, CDKL5 deficiency disorder, and KCNQ2/KCNQ3-related epilepsy — all high-priority orphan programs with high per-patient commercial value
- Gene therapy and antisense oligonucleotide (ASO) trials targeting SCN1A, SCN8A, KCNQ2, and other genetic epilepsy targets — an early but rapidly advancing area with multiple Phase 1/2 programs now open
- Cannabidiol (CBD) combination trials in drug-resistant epilepsy syndromes, building on the Epidiolex approval in Dravet and LGS, and now extending to tuberous sclerosis complex and other rare syndromes
- Neuromodulation device trials — responsive neurostimulation (RNS), vagus nerve stimulation (VNS) improvements, and closed-loop stimulation platforms enrolling in drug-resistant focal epilepsy
Get daily epilepsy trial digest
Set your profile once. Receive a clean digest every morning with new trials and updates matching your criteria.
Start Free — No Credit CardWhat DataLookout monitors for epilepsy
DataLookout pulls directly from the ClinicalTrials.gov API every day. For an epilepsy watch profile, you can configure:
- Condition keywords: "epilepsy", "seizure disorder", "drug-resistant epilepsy", "focal seizures", "Dravet syndrome", "Lennox-Gastaut", "refractory epilepsy", "status epilepticus"
- Phase filter: Phase 1 only, Phase 2/3, or all phases
- Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
- Status filter: Recruiting only, all active studies, or any status
The epilepsy pipeline landscape in 2026
The epilepsy pipeline in 2026 is split between two distinct development tracks that require separate monitoring approaches: the broad drug-resistant epilepsy market and the rare genetic epilepsy orphan segment.
Drug-resistant epilepsy: novel mechanisms beyond sodium channels
The first generation of ASMs (carbamazepine, valproate, phenytoin) primarily targeted sodium channels. The second generation (lamotrigine, levetiracetam, topiramate) added additional mechanisms but did not meaningfully increase the proportion of seizure-free patients. The current pipeline is focused on truly novel mechanisms: selective AMPA receptor antagonists (perampanel opened this class), GABA-A positive allosteric modulators with better CNS penetration, dual sodium/potassium channel modulators, and inhibitors of the mTOR pathway — which is causally implicated in focal cortical dysplasia and tuberous sclerosis complex, two surgically intractable epilepsy syndromes.
Several companies are also developing precision-targeted ASMs for specific genetic subtypes. The commercial rationale is clear: a drug that works specifically in SCN8A-related epilepsy will be used in a small population but will be difficult to replace and will attract orphan pricing. BD teams tracking these trials need to monitor not just recruitment status but the biomarker eligibility criteria — trials that require genetic confirmation before enrollment are advancing a precision medicine paradigm with significant IP implications.
Rare genetic epilepsies: gene therapy enters Phase 2
Gene therapy for epilepsy has moved from preclinical to Phase 1/2 clinical trials for multiple targets. SCN1A haploinsufficiency (Dravet syndrome) is the furthest advanced, with ASO and gene upregulation approaches in early trials. KCNQ2-related neonatal epilepsy, CDKL5 deficiency disorder, and Angelman syndrome (which includes a seizure phenotype) all have active gene therapy or gene editing programs. The regulatory environment is favorable — FDA has granted Rare Pediatric Disease designation and Breakthrough Therapy designation to several programs — and the field is moving fast enough that a six-month lag in monitoring could mean missing a pivotal enrollment opening or a competitor's early Phase 1 results.
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Epilepsy trial on your watchlist. Each change is classified as critical, notable, or minor, so a trial flipping from recruiting to suspended does not read the same as a contact-details edit.
Who uses epilepsy trial monitoring
Pharma and biotech competitive intelligence teams in CNS
Companies developing antiseizure medications or gene therapies for epilepsy face a competitive landscape that spans both a mass-market indication (drug-resistant focal epilepsy, ~1 million patients in the US alone) and a cluster of high-value orphan indications (Dravet, LGS, CDKL5, KCNQ2). CI teams use DataLookout to maintain a comprehensive daily view of who is enrolling, in which epilepsy subtype, at what phase — without manually searching ClinicalTrials.gov each week. Separate watch profiles for "drug-resistant epilepsy" versus "Dravet syndrome" versus "Lennox-Gastaut" allow teams to monitor the full landscape while keeping each digest focused.
Business development teams in neurological disease
Epilepsy is one of the most BD-active areas in CNS. The combination of a large drug-resistant population (clear unmet need, established regulatory endpoints) and multiple rare genetic subtypes (orphan pricing, expedited pathways) creates a wide range of in-licensing and partnering opportunities. BD teams use DataLookout to identify early-stage programs — particularly gene therapy Phase 1/2 trials in rare genetic epilepsies — where results are being generated but have not yet appeared in publications or major conference presentations. Early visibility into a promising Phase 1/2 gene therapy enrollment is often the first signal that a partnership conversation should begin.
Medical affairs and clinical operations teams at epilepsy-focused companies
Medical affairs teams at companies with approved epilepsy products (Epidiolex, Lamictal, Vimpat, Fycompa, etc.) use competitive trial monitoring to track the pipeline that will eventually compete with their products for prescribing share. Knowing when a competitor's Phase 3 trial in drug-resistant focal epilepsy completes enrollment — and estimating the likely readout timeline — helps shape publication strategies, medical education planning, and launch preparation. CRO operations teams use DataLookout to assess the enrollment competition when sizing site feasibility for new epilepsy trial protocols.
Frequently asked questions
How current is the epilepsy trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.
Can I track Dravet syndrome and Lennox-Gastaut separately from broader epilepsy trials?
Yes — and this is one of the most common use cases for epilepsy monitoring. You can set up a profile with "Dravet syndrome" or "SCN1A" as keywords to track only Dravet-specific programs, a separate profile for "Lennox-Gastaut" or "LGS", and a broader profile for "drug-resistant epilepsy" to catch the large unmet-need population. The Starter plan supports up to 5 simultaneous profiles, which covers the most common epilepsy subtype combinations without mixing signals across the full indication landscape.
Does DataLookout cover international trials?
ClinicalTrials.gov includes trials conducted internationally, so yes — international trials registered on ClinicalTrials.gov are included. This covers most major industry-sponsored programs worldwide.
571 active trials, 348 recruiting.
Industry sponsors run 96 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 51.
| Top industry sponsor | Active trials |
|---|---|
| Jazz Pharmaceuticals | 7 |
| Praxis Precision Medicines | 6 |
| UCB Biopharma SRL | 5 |
| Aziende Chimiche Riunite Angelini Francesco S.p.A | 4 |
| Supernus Pharmaceuticals, Inc. | 4 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused… NCT06388707 | Recruiting | Completion pushed: 2027-05-31 → 2027-10-31 | 2026-09-16 |
| RNS System LGS Feasibility Study NCT05339126 | Active, Not Recruiting | Primary completion pushed: 2026-05-31 → 2026-11-30 | 2026-09-16 |
| Neurofeedback Using Implanted Deep Brain Stimulation Electrodes NCT05101161 | Recruiting | Completion pushed: 2026-09-23 → 2028-09-23 | 2026-09-15 |
| Neural Circulatory Control and SUDEP Risk. NCT02813980 | Active, Not Recruiting | Completion pushed: 2030-12 → 2031-12 | 2026-09-12 |
| Evaluation of the NaviFUS System in Drug Resistant Epilepsy NCT05947656 | Recruiting | Completion pushed: 2026-07-01 → 2027-06-01 | 2026-09-11 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.